Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models

Kei KawaguchiAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA;Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan

Kentaro MiyakeAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Ming ZhaoAntiCancer, Inc., San Diego, CA, USA

Tasuku KiyunaAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Kentaro IgarashiAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Masuyo MiyakeAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Takashi HiguchiAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Hiromichi OshiroAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USA

Michael BouvetDepartment of Surgery, University of California, San Diego, CA, USACorrespondence[email protected]

Michiaki UnnoDepartment of Surgery, Graduate School of Medicine, Tohoku University, Sendai, JapanCorrespondence[email protected]

Robert M. HoffmanAntiCancer, Inc., San Diego, CA, USA;Department of Surgery, University of California, San Diego, CA, USACorrespondence[email protected]

show all

Figures & data

Figure 1. Quantitative treatment efficacy.

Bar graphs show relative tumor volume before and after treatment for each treatment condition. (a) Pancreatic cancer PDOX #1. (b) Pancreatic cancer PDOX #2. Error bars: ± SD. Relative tumor volume is the ratio of tumor volume after treatment to the tumor volume before the start of the treatment period.

Figure 2. Effect of each treatment on mouse body weight. Bar graphs show mouse body weight in each treatment group at pre- and post-treatment timepoints. (a) Pancreatic cancer PDOX #1. (b) Pancreatic cancer PDOX #2. Error bars: ± SD.

Figure 3. Tumor histology. (a). Untreated control. (b). Tumor treated with GEM+ S. typhimurium A1-R). Scale bars: 100 μm.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models

Figures & data

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date